Albendazole is a broad-spectrum anthelmintic medication widely used for the treatment of various parasitic worm infections. It belongs to the benzimidazole class of drugs and works primarily by inhibiting microtubule synthesis in parasites, leading to impaired glucose uptake and depletion of energy stores, ultimately causing parasite death.

Clinically, Albendazole 400 mg is indicated for both intestinal and tissue helminthic infections. In intestinal helminthiasis, it is effective against Ascaris lumbricoides (roundworm), Enterobius vermicularis (pinworm), Trichuris trichiura (whipworm), and hookworms (Ancylostoma duodenale, Necator americanus). It is also used in the management of Strongyloides stercoralis and tapeworm infections (Taenia saginata, Taenia solium), though neurocysticercosis due to T. solium larvae requires prolonged and carefully monitored therapy.

Beyond intestinal worms, albendazole plays an important role in treating tissue parasites such as hydatid disease (echinococcosis) caused by Echinococcus granulosus and E. multilocularis. It is also effective in lymphatic filariasis, often in combination with diethylcarbamazine or ivermectin, as part of global eradication programs.
Treatment regimens vary depending on the infection. A single 400 mg dose is often sufficient for common intestinal worms, while prolonged courses (up to weeks or months) are needed for tissue infections like hydatid disease and neurocysticercosis. Safety monitoring, especially liver function and blood counts, is recommended during long-term use.

Overall, albendazole remains a cornerstone in the management of parasitic infections due to its wide efficacy, oral availability, and cost-effectiveness, making it vital in both individual therapy and mass deworming programs.